Journal
PLoS Neglected Tropical Diseases
Publication Date
2021
Volume
15
Issue
2
First Page
e0009069
Document Type
Open Access Publication
DOI
10.1371/journal.pntd.0009069
Rights and Permissions
Jambulingam P, Kuttiatt VS, Krishnamoorthy K, Subramanian S, Srividya A, et al. (2021) An open label, block randomized, community study of the safety and efficacy of co-administered ivermectin, diethylcarbamazine plus albendazole vs. diethylcarbamazine plus albendazole for lymphatic filariasis in India. PLOS Neglected Tropical Diseases 15(2): e0009069. https://doi.org/10.1371/journal.pntd.0009069
Recommended Citation
Jambulingam, Purushothaman; Kuttiatt, Vijesh Sreedhar; Krishnamoorthy, Kaliannagounder; Subramanian, Swaminathan; Srividya, Adinarayanan; Raju, Hari Kishan K.; Rahi, Manju; Somani, Roopali K.; Suryaprakash, Mallanna K.; Dwivedi, Gangeshwar P.; and Weil, Gary J, "An open label, block randomized, community study of the safety and efficacy of co-administered ivermectin, diethylcarbamazine plus albendazole vs. diethylcarbamazine plus albendazole for lymphatic filariasis in India." PLoS Neglected Tropical Diseases. 15, 2. e0009069 (2021).
https://digitalcommons.wustl.edu/open_access_pubs/9999
Shared_INDIA-clinitrial-12month-followup_Final.xlsx (228 kB)
pntd.0009069.s001.pdf (1189 kB)
S1 Protocol. A community based study, to compare the safety, efficacy and acceptability of a triple drug regimen(Ivermectin, Diethylcarbamazine and Albendazole) with a two drug regimen(Diethylcarbamazine and Albendazole) for lymphatic filariasis elimination programme.
pntd.0009069.s002.docx (12 kB)
S1 Table. Participant follow-up rates for assessment of adverse events after treatment.
pntd.0009069.s003.docx (15 kB)
S2 Table. Type of adverse events by severity and treatment regimens.
pntd.0009069.s004.docx (13 kB)
S3 Table. Results of univariate and multivariate analysis of the association of CFA clearance with drug regimen, FTS score at baseline and demographic variables.
pntd.0009069.s005.tif (1144 kB)
S1 Fig. Frequency of the most commonly observed symptoms in Mf-positives among IDA and DA treated subjects.
pntd.0009069.s006.tif (508 kB)
S2 Fig. Frequency of the most commonly observed symptoms in Mf-negatives among IDA and DA treated subjects.
